Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...
After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic lymphocytic leukemia.
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, ...
First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY trial Regimen offers another option for the ...
AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic ...
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the combination regimen of VENCLEXTA® (venetoclax) and ...
The approval was based on the AMPLIFY trial, which evaluated acalabrutinib alongside venetoclax in adults with previously untreated CLL without del(17p) or TP53 mutation.
In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.
FDA cleared acalabrutinib plus venetoclax as the only all-oral, fixed-dose combination option for first-line, treatment-naïve CLL/SLL. Phase 3 AMPLIFY showed superior PFS versus chemoimmunotherapy, ...
The Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) tablets and capsules in combination with Venclexta (venetoclax) for adults with chronic lymphocytic leukemia (CLL) or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results